Zentalis Pharmaceuticals, Inc.
HealthcareNASDAQ:ZNTL · NASDAQ Global Market
+$0.23 today
Vol 0.89M · Avg 1.98M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-63.4%
avg -59.4%
ROIC
-59.6%
avg -54.1%
ROA
-47.4%
avg -43.7%
Analysis
ROA is currently the strongest return metric at -47.4% versus its period average of -43.7%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Julie Eastland | Chief Executive Officer, President & Director | $1.14M | — | 62 | $79,133.00 | 0.11% |
Ingmar Bruns | Chief Medical Officer | $825,952.00 | — | 51 | $33,332.00 | 0.05% |
James Bucher | Chief Legal Officer & Corporate Secretary | $556,683.00 | — | 60 | $100,000.00 | 0.14% |
Henry Gu | Senior Vice President & Head of Intellectual Property | — | — | — | — | — |
Rajesh Israni | Executive VP of Regulatory Affairs & Medical Writing | — | — | — | — | — |
Robert J. DiVasto | Chief Technical Officer | — | — | 70 | — | — |
Vincent Vultaggio | SVP of Finance & Principal Accounting Officer | — | — | 42 | $146,506.00 | 0.21% |
Sarah Kelly | Senior Vice President of Commercial Strategy | — | — | — | — | — |
Haibo Wang | Chief Business Officer | — | — | — | — | — |
Wendy Chang | Chief People Officer | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
1
$7.75M
Sells
10
$10.11M
Net Sentiment
$2.36M
Net selling
Most Active
Vultaggio Vincent
5 transactions
1–10 of 11
Analysis
Insiders reported 1 buys worth $7.75M and 10 sells worth $10.11M over the last 12 months. That adds up to net selling of $2.36M. Vultaggio Vincent was the most active insider with 5 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | N/A | N/A6 analysts |
| Net Income | N/A | N/A | N/A | N/A6 analysts |
| EBIT | N/A | N/A | N/A | N/A6 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Immix Biopharma, Inc.
NASDAQ:IMMX
$459.70M
Sutro Biopharma, Inc.
NASDAQ:STRO
$278.70M
MacroGenics, Inc.
NASDAQ:MGNX
$251.71M
Shattuck Labs, Inc.
NASDAQ:STTK
$236.64M
ALX Oncology Holdings Inc.
NASDAQ:ALXO
$212.61M
Artiva Biotherapeutics, Inc.
NASDAQ:ARTV
$211.08M
Whitehawk Therapeutics Inc
NASDAQ:WHWK
$205.72M
Precision BioSciences, Inc.
NASDAQ:DTIL
$78.25M
Pliant Therapeutics, Inc.
NASDAQ:PLRX
$69.97M
Instil Bio, Inc.
NASDAQ:TIL
$53.71M
Who manages ZNTL?
Zentalis Pharmaceuticals, Inc. (ZNTL) lists 10 active executives. The top listed executive is James Bucher, Chief Legal Officer & Corporate Secretary.
Are ZNTL insiders buying or selling?
Recent insider activity shows net buying of $206.09M.
Explore More
Continue the stock analysis
Jump to another research area for this company.